Kang, SM; Schneider, D; Lin, Z; Hanahan, D; Stock, PG; Baekkeskov, S. 1997. Fas Ligand expression in islets does not confer immune privilege and instead targets them for rapid destruction. Nature Medicine; 3(7):738-743, 1997.

O'Rourke RW, Kang SM, Lower JA, Feng S, Ascher NL, Baekkeskov S, Stock PG. A Dendritic Cell Line Genetically Modified to Express CTLA4-Ig as a Means to Prolong Islet Allograft Survival. Transplantation, 2000 Apr 15, 69(7):1440-6. (UI:20256626)

Kang SM, Braat D, Schneider DB, O'Rourke RW, Lin Z, Ascher NL, Dichek DA, Baekkeskov S, Stock PG. A Non-Cleavable Mutant of Fas Ligand Does Not Prevent Neutrophilic Destruction of Islet Transplants. Transplantation, 2000 May 15, 69(9):1813-7. (UI:20289028)

George J. Chang, MD, Tao Liu, MD, Sandy Feng, MD, PhD, Melanie Bedolli, BS, Robert W. O’Rourke, MD, Gregory Schmidt, BS, John P. Roberts, MD, and Peter G. Stock, MD, PhD. Targeted gene therapy with CD40Ig to induce long-term acceptance of liver allografts. Surgery 2002; 132(2), 149-156.

Roland, ME, Stock, P. Review of Solid Organ Transplantation in HIV-Infected Patients. Transplantation. Volume 75(4): 425